SG11201901063SA - Therapeutic agents for neurodegenerative diseases - Google Patents
Therapeutic agents for neurodegenerative diseasesInfo
- Publication number
- SG11201901063SA SG11201901063SA SG11201901063SA SG11201901063SA SG11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- begbroke
- pct
- neurodegenerative diseases
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| PCT/IB2017/054929 WO2018029658A1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901063SA true SG11201901063SA (en) | 2019-03-28 |
Family
ID=59859424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901063SA SG11201901063SA (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US12144792B2 (enExample) |
| EP (3) | EP3416631B1 (enExample) |
| JP (4) | JP6957602B2 (enExample) |
| KR (4) | KR20220093385A (enExample) |
| CN (4) | CN121081445A (enExample) |
| AU (4) | AU2017308865B2 (enExample) |
| BR (1) | BR112019002730A2 (enExample) |
| CA (1) | CA3033564A1 (enExample) |
| CY (1) | CY1121930T1 (enExample) |
| DK (1) | DK3416631T3 (enExample) |
| ES (1) | ES2733677T3 (enExample) |
| HR (1) | HRP20191055T1 (enExample) |
| HU (1) | HUE045043T2 (enExample) |
| IL (3) | IL264641B2 (enExample) |
| LT (1) | LT3416631T (enExample) |
| MA (2) | MA47521A (enExample) |
| MD (1) | MD3416631T2 (enExample) |
| ME (1) | ME03454B (enExample) |
| MX (3) | MX383499B (enExample) |
| NZ (2) | NZ790893A (enExample) |
| PL (1) | PL3416631T3 (enExample) |
| PT (1) | PT3416631T (enExample) |
| RS (1) | RS59048B1 (enExample) |
| RU (1) | RU2756519C2 (enExample) |
| SG (1) | SG11201901063SA (enExample) |
| SI (1) | SI3416631T1 (enExample) |
| SM (1) | SMT201900370T1 (enExample) |
| TN (1) | TN2019000033A1 (enExample) |
| WO (1) | WO2018029658A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| WO2016210133A1 (en) | 2015-06-24 | 2016-12-29 | The Regents Of The Universtiy Of Michigan | Histotripsy therapy systems and methods for the treatment of brain tissue |
| PT3482754T (pt) | 2016-08-11 | 2021-02-03 | Intrabio Ltd | Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico |
| TN2019000033A1 (fr) | 2016-08-11 | 2020-07-15 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US11793782B2 (en) * | 2017-10-18 | 2023-10-24 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| RS65663B1 (sr) | 2018-02-15 | 2024-07-31 | Intrabio Ltd | Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu |
| US11813484B2 (en) | 2018-11-28 | 2023-11-14 | Histosonics, Inc. | Histotripsy systems and methods |
| CN120157593A (zh) * | 2018-12-06 | 2025-06-17 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| CN119097618A (zh) * | 2019-03-02 | 2024-12-10 | 内在生物技术有限公司 | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 |
| MD3989962T2 (ro) | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| CN114727761A (zh) * | 2019-09-17 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 患有运动障碍的患者的个性化保健的改善 |
| WO2021144720A1 (en) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| KR20230015433A (ko) * | 2020-05-22 | 2023-01-31 | 인트라바이오 리미티드 | 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물 |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| US20240149078A1 (en) | 2022-10-28 | 2024-05-09 | Histosonics, Inc. | Histotripsy systems and methods |
| JP2026516719A (ja) | 2023-04-20 | 2026-05-26 | ヒストソニックス，インコーポレーテッド | 治療計画および治療のためのユーザインターフェースとワークフローとを含むヒストトリプシーシステムおよび関連方法 |
| WO2025090672A1 (en) | 2023-10-23 | 2025-05-01 | Histosonics, Inc. | Histotripsy systems and methods |
| CN122055147A (zh) * | 2024-01-12 | 2026-05-15 | 内在生物技术股份有限公司 | 用于治疗前驱期α-突触核蛋白病的N-乙酰亮氨酸 |
| WO2025163129A1 (en) * | 2024-02-01 | 2025-08-07 | Intrabio Ltd. | Acetyl-leucine for treating parkinson´s disease |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (en) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acetyl leucine for treating syngap1-related disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| FR2905600B1 (fr) | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| DE202008018253U1 (de) | 2007-02-22 | 2012-05-21 | Beiersdorf Ag | Kosmetische und pharmazeutische Anwendungen von N-Acethylhydroxyprolin |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| US9745342B2 (en) * | 2013-10-28 | 2017-08-29 | Naurex, Inc. | NMDA receptor modulators and prodrugs, salts, and uses thereof |
| PT3445351T (pt) | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| TN2019000033A1 (fr) | 2016-08-11 | 2020-07-15 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
-
2017
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 CA CA3033564A patent/CA3033564A1/en active Pending
- 2017-08-11 NZ NZ790893A patent/NZ790893A/en unknown
- 2017-08-11 US US16/324,353 patent/US12144792B2/en active Active
- 2017-08-11 CN CN202511449973.8A patent/CN121081445A/zh active Pending
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/en active Active
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 NZ NZ750421A patent/NZ750421A/en unknown
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active Ceased
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active Active
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/en not_active Ceased
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 KR KR1020257008819A patent/KR20250042197A/ko active Pending
- 2017-08-11 EP EP19174007.5A patent/EP3583940B1/en active Active
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 IL IL264641A patent/IL264641B2/en unknown
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt not_active Application Discontinuation
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/me unknown
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 EP EP24191483.7A patent/EP4467195A3/en active Pending
- 2017-08-11 MX MX2019001575A patent/MX383499B/es unknown
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 KR KR1020247014635A patent/KR102785448B1/ko active Active
- 2017-08-11 SM SM20190370T patent/SMT201900370T1/it unknown
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP7833272B2/ja active Active
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121B2/en active Active
- 2023-09-08 JP JP2023146465A patent/JP7885184B2/ja active Active
-
2024
- 2024-01-12 US US18/411,512 patent/US20240189267A1/en active Pending
- 2024-04-11 MX MX2024004439A patent/MX2024004439A/es unknown
-
2025
- 2025-03-21 AU AU2025202077A patent/AU2025202077B2/en active Active
-
2026
- 2026-02-27 US US19/552,356 patent/US20260191808A1/en active Pending
- 2026-02-27 JP JP2026031148A patent/JP2026094294A/ja active Pending
- 2026-05-08 AU AU2026203549A patent/AU2026203549A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201908159QA (en) | Dual magl and faah inhibitors | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201907153RA (en) | Topical formulations and methods | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |